60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.16), FiscalAI reports. The business had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.18 million.
60 Degrees Pharmaceuticals Trading Up 1.3%
NASDAQ SXTP traded up $0.01 during trading on Friday, hitting $1.20. 150,822 shares of the company’s stock were exchanged, compared to its average volume of 1,870,604. 60 Degrees Pharmaceuticals has a fifty-two week low of $1.05 and a fifty-two week high of $8.62. The company has a market cap of $3.18 million, a PE ratio of -0.13 and a beta of 2.54. The stock’s 50 day moving average price is $1.47 and its two-hundred day moving average price is $2.02.
Analyst Upgrades and Downgrades
Several research firms have recently commented on SXTP. HC Wainwright downgraded 60 Degrees Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Ascendiant Capital Markets decreased their price target on 60 Degrees Pharmaceuticals from $4.20 to $3.70 and set a “buy” rating on the stock in a research report on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, 60 Degrees Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $13.85.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.
See Also
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
